Ionis Pharmaceuticals Inc at BMO Biopharma Day: Spotlight on Rare Disease and Ophthalmology (Virtual) Transcript
Hi, everyone. I'm Gary Nachman, the biopharma analyst at BMO, and we're very excited to have Eric Swayze, Head of Research at Ionis with us.
Ionis is a great platform in antisense technology with a very robust portfolio in neurology and cardiovascular disease and has been a major player in rare disease for a long time. So really great to have you here, Eric, to chat with us. Thanks for being here.
Great. I'm happy to be here and join you, Gary. Thanks for the opportunity to chat.
Questions & Answers
Okay. Great. So maybe you can start by just giving a brief overview of the company's antisense technology and just the flexibility that you have to modulate all different types of RNA. So how broad that technology could take you and has it taken you with your pipeline?
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |